SE429405B - Sett att framstella influensavaccin innhallande aterforenade, seruminhibitorresistenta virusstammar - Google Patents
Sett att framstella influensavaccin innhallande aterforenade, seruminhibitorresistenta virusstammarInfo
- Publication number
- SE429405B SE429405B SE7412113A SE7412113A SE429405B SE 429405 B SE429405 B SE 429405B SE 7412113 A SE7412113 A SE 7412113A SE 7412113 A SE7412113 A SE 7412113A SE 429405 B SE429405 B SE 429405B
- Authority
- SE
- Sweden
- Prior art keywords
- strain
- serum
- virus
- eggs
- influenza virus
- Prior art date
Links
- 210000002966 serum Anatomy 0.000 title claims description 52
- 241000700605 Viruses Species 0.000 title claims description 34
- 239000003112 inhibitor Substances 0.000 title claims description 26
- 239000000126 substance Substances 0.000 title 1
- 241000712461 unidentified influenza virus Species 0.000 claims description 27
- 235000013601 eggs Nutrition 0.000 claims description 24
- 238000010790 dilution Methods 0.000 claims description 19
- 239000012895 dilution Substances 0.000 claims description 19
- 241000700199 Cavia porcellus Species 0.000 claims description 9
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 9
- 238000000034 method Methods 0.000 claims description 9
- 239000000463 material Substances 0.000 claims description 8
- 241000287828 Gallus gallus Species 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 230000003612 virological effect Effects 0.000 claims description 6
- 230000002238 attenuated effect Effects 0.000 claims description 5
- 206010022000 influenza Diseases 0.000 claims description 3
- 229940124873 Influenza virus vaccine Drugs 0.000 claims description 2
- 241000282339 Mustela Species 0.000 description 14
- 229960005486 vaccine Drugs 0.000 description 13
- 241000283073 Equus caballus Species 0.000 description 8
- 230000035931 haemagglutination Effects 0.000 description 6
- 238000011081 inoculation Methods 0.000 description 6
- 239000000203 mixture Substances 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 239000001888 Peptone Substances 0.000 description 5
- 108010080698 Peptones Proteins 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 235000019319 peptone Nutrition 0.000 description 5
- 230000000694 effects Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000002054 inoculum Substances 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000002163 immunogen Effects 0.000 description 2
- 229940099472 immunoglobulin a Drugs 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000036512 infertility Effects 0.000 description 2
- 229960003971 influenza vaccine Drugs 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 1
- 206010028735 Nasal congestion Diseases 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 244000309464 bull Species 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 229940037525 nasal preparations Drugs 0.000 description 1
- 210000001989 nasopharynx Anatomy 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- 230000000405 serological effect Effects 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/543—Mucosal route intranasal
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Virology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/401,335 US3953592A (en) | 1973-09-27 | 1973-09-27 | Live influenza virus vaccines and preparation thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SE7412113L SE7412113L (de) | 1975-04-01 |
| SE429405B true SE429405B (sv) | 1983-09-05 |
Family
ID=23587327
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SE7412113A SE429405B (sv) | 1973-09-27 | 1974-09-26 | Sett att framstella influensavaccin innhallande aterforenade, seruminhibitorresistenta virusstammar |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US3953592A (de) |
| JP (1) | JPS5058223A (de) |
| AT (1) | AT331978B (de) |
| BE (1) | BE819865A (de) |
| CA (1) | CA1030450A (de) |
| CH (1) | CH595447A5 (de) |
| CS (1) | CS203080B2 (de) |
| DD (1) | DD114966A5 (de) |
| DE (1) | DE2445819A1 (de) |
| DK (1) | DK508274A (de) |
| ES (1) | ES430415A1 (de) |
| FI (1) | FI278774A (de) |
| FR (1) | FR2245376B1 (de) |
| GB (1) | GB1461188A (de) |
| HU (1) | HU169383B (de) |
| IE (1) | IE40180B1 (de) |
| IL (1) | IL45589A (de) |
| LU (1) | LU70998A1 (de) |
| NL (1) | NL7411746A (de) |
| NO (1) | NO743433L (de) |
| SE (1) | SE429405B (de) |
| ZA (1) | ZA745571B (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6042209B2 (ja) * | 1974-05-31 | 1985-09-20 | 北里研究所（社団法人） | インフルエンザウイルスの新鮮分離株を発育鶏卵へ短期間で順化させる方法 |
| US4318903A (en) * | 1978-07-12 | 1982-03-09 | Smithkline-Rit | Live influenza virus vaccine and the preparation thereof |
| US4278662A (en) * | 1979-10-16 | 1981-07-14 | Smith Kline - Rit | Attenuated influenza type A virus vaccine |
| JPS59163313A (ja) * | 1983-03-09 | 1984-09-14 | Teijin Ltd | 経鼻投与用ペプチドホルモン類組成物 |
| US4783411A (en) * | 1984-10-22 | 1988-11-08 | Janis Gabliks | Influenza-A virus vaccine from fish cell cultures |
| NZ224422A (en) * | 1987-05-05 | 1990-11-27 | Molecular Eng Ass | Composition adapted for intranasal immunisation against viral infection comprising a glycoprotein complexed with a lipid |
| US7678087B2 (en) * | 1999-09-29 | 2010-03-16 | Heska Corporation | Equine intranasal delivery system |
| US6398774B1 (en) | 1999-09-29 | 2002-06-04 | Heska Corporation | Intranasal delivery system |
| ES2784189T3 (es) | 2009-03-27 | 2020-09-23 | Academia Sinica | Métodos y composiciones para la inmunización contra virus |
| TWI537385B (zh) | 2010-11-04 | 2016-06-11 | 中央研究院 | 產生具簡單醣基化之表面蛋白質之病毒顆粒的方法 |
-
1973
- 1973-09-27 US US05/401,335 patent/US3953592A/en not_active Expired - Lifetime
-
1974
- 1974-08-28 CH CH1173374A patent/CH595447A5/xx not_active IP Right Cessation
- 1974-08-29 CA CA208,125A patent/CA1030450A/en not_active Expired
- 1974-08-30 ZA ZA00745571A patent/ZA745571B/xx unknown
- 1974-09-04 IL IL45589A patent/IL45589A/en unknown
- 1974-09-04 NL NL7411746A patent/NL7411746A/xx not_active Application Discontinuation
- 1974-09-13 FR FR7431029A patent/FR2245376B1/fr not_active Expired
- 1974-09-13 BE BE148474A patent/BE819865A/xx not_active IP Right Cessation
- 1974-09-21 JP JP49109440A patent/JPS5058223A/ja active Pending
- 1974-09-24 CS CS746552A patent/CS203080B2/cs unknown
- 1974-09-24 NO NO743433A patent/NO743433L/no unknown
- 1974-09-25 LU LU70998A patent/LU70998A1/xx unknown
- 1974-09-25 FI FI2787/74A patent/FI278774A/fi unknown
- 1974-09-25 DE DE19742445819 patent/DE2445819A1/de not_active Ceased
- 1974-09-26 GB GB4184974A patent/GB1461188A/en not_active Expired
- 1974-09-26 AT AT776074A patent/AT331978B/de active
- 1974-09-26 HU HURE565A patent/HU169383B/hu unknown
- 1974-09-26 DD DD181344A patent/DD114966A5/xx unknown
- 1974-09-26 IE IE1994/74A patent/IE40180B1/xx unknown
- 1974-09-26 DK DK508274A patent/DK508274A/da unknown
- 1974-09-26 SE SE7412113A patent/SE429405B/sv unknown
- 1974-09-26 ES ES430415A patent/ES430415A1/es not_active Expired
Also Published As
| Publication number | Publication date |
|---|---|
| CH595447A5 (de) | 1978-02-15 |
| LU70998A1 (de) | 1975-03-06 |
| SE7412113L (de) | 1975-04-01 |
| CS203080B2 (en) | 1981-02-27 |
| AT331978B (de) | 1976-09-10 |
| US3953592A (en) | 1976-04-27 |
| ZA745571B (en) | 1975-09-24 |
| IE40180B1 (en) | 1979-03-28 |
| ATA776074A (de) | 1975-12-15 |
| BE819865A (fr) | 1975-03-13 |
| ES430415A1 (es) | 1977-02-01 |
| FR2245376A1 (de) | 1975-04-25 |
| JPS5058223A (de) | 1975-05-21 |
| FI278774A (de) | 1975-03-28 |
| DK508274A (de) | 1975-06-02 |
| CA1030450A (en) | 1978-05-02 |
| DE2445819A1 (de) | 1975-04-10 |
| GB1461188A (en) | 1977-01-13 |
| DD114966A5 (de) | 1975-09-05 |
| HU169383B (de) | 1976-11-28 |
| AU7330674A (en) | 1976-03-18 |
| NL7411746A (nl) | 1975-04-02 |
| IL45589A0 (en) | 1974-11-29 |
| IE40180L (en) | 1975-03-27 |
| IL45589A (en) | 1977-05-31 |
| FR2245376B1 (de) | 1978-07-28 |
| NO743433L (de) | 1975-04-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4693893A (en) | Vaccines for equine influenza | |
| Takada et al. | Avirulent Avian influenza virus as a vaccine strain against a potential human pandemic | |
| Virelizier | Host defenses against influenza virus: the role of anti-hemagglutinin antibody | |
| US5762939A (en) | Method for producing influenza hemagglutinin multivalent vaccines using baculovirus | |
| EP0891420B1 (de) | Verfahren fuer die replikation von influenza in zellkultur und die bei diesem verfahren hergestellten influenza-viren | |
| US5597721A (en) | Preparation of antigens of and of vaccines for the virus of mystery disease, antigens and vaccines obtained for the prevention of this disease | |
| US6048537A (en) | Method for preparing an influenza virus, antigens obtained and applications thereof | |
| KR20090088944A (ko) | 배양물 속에서 인플루엔자 바이러스를 복제하는 방법 | |
| EP0279563B1 (de) | Influenza-Impfstoff | |
| SE429405B (sv) | Sett att framstella influensavaccin innhallande aterforenade, seruminhibitorresistenta virusstammar | |
| JP2014511119A (ja) | Ｈ１ｎ１亜型インフルエンザパンデミックウイルスに対する新型ワクチン | |
| Hooks et al. | Characterization and distribution of two new foamy viruses isolated from chimpanzees | |
| RU2757723C2 (ru) | Рекомбинантные вирусоподобные частицы (vlp) с использованием протеина группового антигена (gag) вируса бычьего иммунодефицита | |
| AU2002253542B2 (en) | Purified subfragment encoding neuroaminidase, recombinant neuroaminidase and its use in zooprophylaxis | |
| Kono et al. | An epidemic of Getah virus infection among racehorses: properties of the virus | |
| EA024262B1 (ru) | СПОСОБ ПОЛУЧЕНИЯ ВЫСОКОИНФЕКЦИОННОГО ВИРУСА ГРИППА, СТАБИЛЬНОГО ПРИ НИЗКИХ pH | |
| Della-Porta et al. | Bovine ephemeral fever virus | |
| CA1152895A (en) | Process for the preparation of novel influenza virus strains and influenza virus vaccines containing them | |
| Van Kirk et al. | Evaluation of low temperature grown influenza A2/Hong Kong virus in volunteers | |
| Scott et al. | Respiratory syncytial virus neutralizing activity in nasopharyngeal secretions | |
| CN107384875A (zh) | 克服雏鸡新城疫母源抗体影响的嵌合新城疫病毒载体h7活疫苗候选株及其构建方法 | |
| EP0105364B1 (de) | Temperaturempfindliche reassortierende viren und impfstoff gegen pferdeinfluenza | |
| Kilbourne et al. | Hemagglutinin mutants of swine influenza virus differing in replication characteristics in their natural host | |
| KR101627623B1 (ko) | 이종 인플루엔자 바이러스에 대한 백신 조성물 | |
| KR20130130326A (ko) | 신규한 개 인플루엔자 바이러스(ｈ３ｎ２), 이를 포함하는 백신 조성물 및 ｈ３ｎ２ 바이러스 검정 키트 |